Form 4: Glaukos Director Receives RSU Grant

Glaukos Corporation's Director, David F. Hoffmeister, was granted 753 restricted stock units as part of the company's director compensation policy.

Summary

• David F. Hoffmeister, a Director of Glaukos Corporation, received a grant of 753 restricted stock units (RSUs) on January 2, 2026.
• The RSUs were granted at a price of $0, indicating they are part of a compensation package under the Issuer's Director Compensation Policy.
• These units are scheduled to vest in full on the one-year anniversary of the grant date and will be payable in an equivalent number of Glaukos common stock shares.
• Following this transaction, Hoffmeister directly beneficially owns 32,671 shares and indirectly owns 38,176 shares through Sentinel Point Partners, Inc.
• The direct beneficial ownership includes 2,861 unvested restricted stock units and other restricted stock units that have vested but whose delivery has been deferred.
• The transaction was made pursuant to a Rule 10b5-1(c) plan.

Sentiment

Score: 7

Explanation: A routine insider RSU grant, generally positive as it aligns director interests with shareholders, but not a major market-moving event.

Positives

• Director David F. Hoffmeister received a grant of 753 restricted stock units, aligning his interests with long-term shareholder value.
• The grant is part of the Issuer's Director Compensation Policy, indicating a structured approach to executive incentives.

Future Outlook

The restricted stock units granted to Director Hoffmeister are scheduled to vest in full on the one-year anniversary of the grant date (January 2, 2027), indicating a future delivery of common stock.

Industry Context

This transaction is a routine insider compensation event, common across publicly traded companies, particularly for non-employee directors, to align their interests with long-term company performance and shareholder value within the medical technology sector.

Comparison to Industry Standards

• The grant of restricted stock units to a director is a standard practice in corporate governance and executive compensation across various industries, including the medical technology sector where Glaukos operates.
• This method is widely used to incentivize long-term commitment and performance, aligning director interests with those of shareholders.
• No specific comparable companies, projects, or results are mentioned in this filing for direct comparison.

Stakeholder Impact

• Shareholders: The RSU grant aligns the director's financial interests with long-term shareholder value, potentially fostering decisions that benefit the company's stock performance.

Next Steps

• The restricted stock units are expected to vest in full on the one-year anniversary of the grant date (January 2, 2027), at which point they will be payable in common stock.

Key Dates

Recommendation

This Form 4 reports a routine grant of restricted stock units to a director as part of their compensation. Such grants are standard practice to align director interests with long-term shareholder value and do not typically indicate a change in the company's fundamental outlook or warrant a change in investment recommendation based solely on this filing.

Keywords

Glaukos Corporation, GKOS, Form 4, Restricted Stock Units, RSU Grant, Director Compensation, Insider Transaction, David F Hoffmeister, Equity Compensation